- Home
- CBNA vs VTYX Comparison
CBNA vs VTYX Comparison
Compare CBNA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- VTYX
- Stock Information
- Founded
- CBNA 2006
- VTYX 2018
- Country
- CBNA United States
- VTYX United States
- Employees
- CBNA N/A
- VTYX N/A
- Industry
- CBNA
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- CBNA
- VTYX Health Care
- Exchange
- CBNA NYSE
- VTYX Nasdaq
- Market Cap
- CBNA 159.8M
- VTYX 154.9M
- IPO Year
- CBNA 2024
- VTYX 2021
- Fundamental
- Price
- CBNA $24.48
- VTYX $1.07
- Analyst Decision
- CBNA Buy
- VTYX Buy
- Analyst Count
- CBNA 3
- VTYX 4
- Target Price
- CBNA $29.67
- VTYX $11.33
- AVG Volume (30 Days)
- CBNA 14.0K
- VTYX 1.4M
- Earning Date
- CBNA 05-15-2025
- VTYX 05-08-2025
- Dividend Yield
- CBNA N/A
- VTYX N/A
- EPS Growth
- CBNA 115.79
- VTYX N/A
- EPS
- CBNA 4.17
- VTYX N/A
- Revenue
- CBNA $53,113,000.00
- VTYX N/A
- Revenue This Year
- CBNA N/A
- VTYX N/A
- Revenue Next Year
- CBNA $22.92
- VTYX N/A
- P/E Ratio
- CBNA $5.87
- VTYX N/A
- Revenue Growth
- CBNA 74.81
- VTYX N/A
- 52 Week Low
- CBNA $20.01
- VTYX $0.78
- 52 Week High
- CBNA $27.56
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- VTYX 42.90
- Support Level
- CBNA N/A
- VTYX $1.02
- Resistance Level
- CBNA N/A
- VTYX $1.18
- Average True Range (ATR)
- CBNA 0.00
- VTYX 0.11
- MACD
- CBNA 0.00
- VTYX 0.03
- Stochastic Oscillator
- CBNA 0.00
- VTYX 65.98
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.